                         SEQUENCE LISTING

<110>  The Regents of the University of Michigan
       Ascenta Therapeutics, Inc.
       Sanofi
 
<120>  Spiro-Oxindole MDM2 Antagonists

<130>  UM-31692/WO-1/ORD

<150>  US 61/451,968
<151>  2011-03-11

<150>  US 61/413,094
<151>  2010-11-12

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  The residue at this position is linked to 5-Carboxyfluorescein

<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  The residues at these positions are beta-alanine

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  The residue at this position is alpha-aminoisobutyric acid

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  The residue at this position is phosphotyrosine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  The residue at this position is 6-C1-LTrp

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  The residue at this position is 1-amino-cyclopropanecarboxylic 
       acid

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  The residue at this position is linked to NH2

<400>  1

Ala Ala Phe Met Xaa Tyr Trp Glu Xaa Leu Asn 
1               5                   10      


